Dermatology

Login Register

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Home

emcure pharma

Tag: emcure pharma

Read all Latest developments, information and news on and about emcure pharma - Page 3

Emcure Pharma is an Indian pharmaceutical company headquartered in Pune, Maharashtra. Emcure's product portfolio includes tablets, capsules, and injectables.

HC restrains pharma companies from infringing Boehringer Ingelheim diabetes drug Linagliptin

Susmita Roy8 Jun 2022 4:04 PM IST

New Delhi: In a major relief to pharmaceuticals major Boehringer Ingelheim, the High Court has restrained four domestic pharma companies namely,...

NPPA fixes price of 84 formulations, revises 1

Ruchika Sharma13 May 2022 3:00 PM IST

New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of 84 formulations and has...

Ahead of Linagliptin going off-patent, NPPA fixes retail price of its FDC with Metformin

Susmita Roy20 April 2022 6:57 PM IST

New Delhi: With the popular antidiabetic drug Linagliptin soon expected to go off-patent, the apex drug price regulator, National Pharmaceutical...

NPPA fixes retail prices of 15 formulations, ceiling price of Framycetin

Ruchika Sharma19 April 2022 4:06 PM IST

New Delhi: National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India has fixed retail prices of 15...

Emcure Pharma Expands Its Dermatology Portfolio

Bain Capital backed Emcure Pharma files draft IPO papers with SEBI

Ruchika Sharma20 Aug 2021 1:09 PM IST

New Delhi: Bain Capital-backed Emcure Pharmaceuticals has filed preliminary papers with capital markets regulator Sebi to raise funds through an...

Setback to Emcure: NPPA refers back price fixation issue of Darunavir, Ritonavir FDC to DoP

Medical Dialogues Team9 Aug 2021 2:14 PM IST

New Delhi: Holding that data is not available, the National Pharmaceuticals Pricing Authority (NPPA) has referred the matter of fixing the retail...

Emcure Pharma eyes to be among top 5 drug firms: Official

Ruchika Sharma9 Aug 2021 1:00 PM IST

New Delhi: Emcure Pharmaceuticals is aiming to be among the top five drug firms in the country in the next five to seven years as it also eyes...

5 pharma firms tapping IPO market to raise over Rs 8000 crore

Ruchika Sharma3 Aug 2021 10:00 AM IST

Mumbai: Riding on huge investor interest in the healthcare sector, five pharma companies are tapping the initial public offering (IPO) market over the...

Emcure Pharma includes 4 new independent directors

Ruchika Sharma28 July 2021 12:00 PM IST

New Delhi: Emcure Pharmaceuticals on Tuesday said it has strengthened its board with the inclusion of four new independent directors, including former...

MSD in talks with 5 Indian drugmakers for clinical trial of COVID drug Molnupiravir

Medical Dialogues Team30 Jun 2021 5:28 PM IST

New Delhi: MSD Pharmaceuticals, the wholly owned subsidiary of Merck Sharp Dohme, known as Merck & Co in the US, announced that it has decided to...

DoP directs NPPA to fix price of Darunavir, Ritonavir for Emcure Pharma

Medical Dialogues Team29 Jun 2021 5:09 PM IST

New Delhi: The Department of Pharmaceuticals (DoP), has recently directed the National Pharmaceuticals Pricing Authority (NPPA) to fix the retail...

Emcure, Glenmark arm, 3 others line up Rs 7000 crore IPOs

Ruchika Sharma28 May 2021 1:00 PM IST

Mumbai: Amidst the raging second wave of the COVID-19 pandemic and many fearing a third wave, the healthcare sector is in the limelight for the...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok